DexCom, Inc. $DXCM Shares Sold by HighTower Advisors LLC

HighTower Advisors LLC lowered its stake in DexCom, Inc. (NASDAQ:DXCM) by 88.3% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 53,446 shares of the medical device company’s stock after selling 401,822 shares during the quarter. HighTower Advisors LLC’s holdings in DexCom were worth $3,596,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of the stock. Aberdeen Group plc lifted its position in shares of DexCom by 59.2% in the third quarter. Aberdeen Group plc now owns 486,373 shares of the medical device company’s stock valued at $32,490,000 after acquiring an additional 180,943 shares in the last quarter. GF Fund Management CO. LTD. raised its stake in DexCom by 2.0% in the 3rd quarter. GF Fund Management CO. LTD. now owns 88,848 shares of the medical device company’s stock valued at $5,979,000 after purchasing an additional 1,780 shares during the last quarter. Freemont Management S.A. purchased a new position in DexCom in the 3rd quarter valued at about $404,000. Wedbush Securities Inc. boosted its stake in shares of DexCom by 2.5% during the 3rd quarter. Wedbush Securities Inc. now owns 13,537 shares of the medical device company’s stock worth $911,000 after purchasing an additional 327 shares during the last quarter. Finally, Cibc World Market Inc. boosted its stake in shares of DexCom by 1.1% during the 3rd quarter. Cibc World Market Inc. now owns 32,006 shares of the medical device company’s stock worth $2,154,000 after purchasing an additional 355 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

DXCM has been the topic of several recent analyst reports. Leerink Partners reissued an “outperform” rating and set a $92.00 price objective on shares of DexCom in a research note on Tuesday, December 16th. Wells Fargo & Company reduced their price target on DexCom from $93.00 to $85.00 and set an “overweight” rating on the stock in a research note on Friday, February 13th. TD Cowen lowered their price objective on DexCom from $100.00 to $84.00 and set a “buy” rating for the company in a research report on Friday, October 31st. Truist Financial reiterated a “buy” rating and set a $80.00 target price (down from $82.00) on shares of DexCom in a research report on Tuesday, February 17th. Finally, Argus decreased their price target on DexCom from $100.00 to $90.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, four have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $85.18.

DexCom Price Performance

DXCM opened at $73.19 on Thursday. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $90.66. The company has a 50 day moving average of $69.92 and a two-hundred day moving average of $69.22. The company has a market cap of $28.17 billion, a P/E ratio of 34.85, a P/E/G ratio of 1.42 and a beta of 1.49. The company has a quick ratio of 1.59, a current ratio of 1.88 and a debt-to-equity ratio of 0.45.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.03. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The business had revenue of $1.26 billion for the quarter, compared to analyst estimates of $1.25 billion. During the same quarter in the previous year, the business posted $0.45 EPS. The business’s quarterly revenue was up 13.1% on a year-over-year basis. On average, analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.